Press "Enter" to skip to content

Bristol-Myers wins $752 million in U.S. patent case against Gilead

A jury in Los Angeles awarded the damages after finding that Yescarta, a treatment sold by Gilead’s Kite Pharma unit, infringed on a patent exclusively licensed by Bristol-Myers’ Juno Therapeutics division.

Original source:

Also Read:   Scientists identify hundreds of drug candidates to treat Covid-19